ArticleJournal of cannabis research2026
Sex differences in the disposition of cannabidiol and its metabolites in mice.
Article in Journal of cannabis research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cannabidiol attenuates chemotherapy-induced peripheral neuropathic pain through a mechanism that requires the enzymebioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundWhile cannabidiol (CBD) is widely used globally as a therapeutic agent, sex as a biological variable remains underexplored in determining its metabolism and overall pharmacokinetic patterns. The present study systematically evaluated sex differences in the pharmacokinetics of CBD and its major metabolites, 7-hydroxy-CBD (7-OH-CBD) and 7-carboxy-CBD (7-COOH-CBD), in a mouse model.
methodsMale and female C57BL/6J mice received an intraperitoneal dose of CBD (120 mg/kg) and plasma concentrations of CBD and its metabolites were quantified by UPLC-MS/MS. Pharmacokinetic parameters were derived using non-compartmental analysis and compared between sexes.
resultsFemales exhibited significantly higher early exposure to CBD, with a ~ 1.5-fold higher [Formula: see text]than male mice (p = 0.03). The apparent clearance (CL/F) and ultimate total systemic exposure[Formula: see text] were comparable between sexes. In contrast, male mice demonstrated a markedly larger apparent volume of distribution (Vz/F; ~2.2-fold increase, p = 0.02) and consequently a longer terminal half-life (t
conclusionsThese results demonstrate that sex is a critical determinant of CBD pharmacokinetics and highlight the need for sex-informed dosing considerations in both preclinical study design and potentially for future clinical applications of CBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.